Novartis loses latest bid to block generic version of blockbuster heart drug

Novartis (NOVN.S) has lost a bid to keep a generic version of its top-selling heart failure drug Entresto off the U.S. market by blocking regulators from approving it, though the generic's launch faces other legal roadblocks.